TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02988609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: fMRI at 3 different times after concussion: just after concussion (V1), once players have clinically recovered (V2) and 3 months after V2 (V3).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: fMRI at 3 different times after concussion: just after concussion (V1), once players have clinically recovered (V2) and 3 months after V2 (V3).
Study: NCT03483103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lisocabtagene maraleucel
Description: lisocabtagene maraleucel will be administered as a single dose intravenous (IV) injection
Study: NCT00699751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Radium-223 dichloride 50 kBq/kg b.w., 6 IV administrations separated by 4 weeks intervals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic saline 6 IV administrations separated by 4 weeks intervals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Best standard of care (BSoC)
Description: Best standard of care is regarded as the routine standard of care at each center, for example local EBRT (External Beam Radiation Therapy), corticosteroids, antiandrogens, estrogens (e.g., stilboestrol), estramustine or ketoconazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best standard of care (BSoC)
Description: Best standard of care is regarded as the routine standard of care at each center, for example local EBRT (External Beam Radiation Therapy), corticosteroids, antiandrogens, estrogens (e.g., stilboestrol), estramustine or ketoconazole.
Study: NCT00762905

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LiquiBand Laparoscopic
Description: LiquiBand Laparoscopic™ is a sterile, liquid adhesive made up of a blend of n-butyl and 2-octyl cyanoacrylate intended for soft tissue approximation of skin wounds. It is packaged in a sterile, single-use, nylon applicator with internal glass ampoule containing 0.8g of adhesive and sealed in a PETG/Tyvek blister pack. LiquiBand Laparoscopic™ is intended to be applied topically to pre-apposed wound edges. The tissue adhesive sets rapidly (5 - 10 seconds) to hold the wound closed. Following wound closure the product is designed to apply a broad coverage of adhesive to act as a liquid dressing to protect the wound.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabond
Description: High viscosity DermaBond Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D \& C Violet #2. It is provided in a single use applicator packaged in a blister pouch. The applicator is comprised of a crushable glass ampule contained within a plastic vial with attached applicator tip. As applied to skin, the liquid is syrup-like in viscosity and polymerizes within minutes.
Study: NCT00756301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lidocaine local anesthesia- Alternative
Description: Local anesthetic (Lidocaine) injected using traditional technique (involves injecting Lidocaine into the skin first, then into the deeper tissues).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine local anesthesia- Alternative
Description: Local anesthetic (Lidocaine) injected using traditional technique (involves injecting Lidocaine into the skin first, then into the deeper tissues).
Study: NCT01348269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aclasta
Description: 1 x intravenous non-current drip (infusion)
Study: NCT01059929

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical and Occupational Therapy
Description: Daily therapy sessions targeting range of motion, strength, and mobility

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical and Occupational Therapy
Description: Daily therapy sessions targeting range of motion, strength, and mobility
Study: NCT00344890

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion
Description: 1,2,3,or 4 level surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Cervical Discectomy and Fusion
Description: 1,2,3,or 4 level surgery
Study: NCT02447705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telbivudine
Description: telbivudine replace Lamivudine
Study: NCT01456910

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training Program
Description: Frequency, volume, repetitions, load, interval

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training Program
Description: Frequency, volume, repetitions, load, interval
Study: NCT00388427

Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib (BMS-354825)
Description: 100 mg, 150 mg, or 200 mg per dose escalation schedule; continuous oral dosing on Days 1-21 of each 21-day cycle until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: OTHER
Intervention: Cetuximab (Erbitux, C225)
Description: Loading dose of IV 400 mg/m\^2 on Day 1 of Cycle 1; IV 250 mg/m\^2 weekly thereafter each 21-day cycle until progression or unacceptable toxicity develops.
Study: NCT01047098

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron
Description: Iron as iron sulfate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron
Description: Iron as iron sulfate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT04192227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EnHAncing BehavIors through wellness TreatmentS (HABITS)
Description: Six 75-minute sessions via live video conference wherein participants will receive training in areas of health, wellness and quality of life. Classes will be supplemented with independent homework assignments and discussion on a closed social media forum with peers and facilitators.
Study: NCT04604327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemiparin sodium
Description: Prophilactic vs full-dose for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bemiparin sodium
Description: Prophilactic vs full-dose for 10 days
Study: NCT01348269

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl Solution
Study: NCT03787407

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stress management and meditation
Description: mindfulness training using mobile application

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stress management and meditation
Description: mindfulness training using mobile application
Study: NCT02189824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Partially HLA-matched unrelated donor cells
Study: NCT02242344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02565251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flotrac/Ev1000
Description: Hemodynamic resusucitation guided by the data obtained from the monitorisation with Flotrac/Ev1000 device in the first two hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flotrac/Ev1000
Description: Hemodynamic resusucitation guided by the data obtained from the monitorisation with Flotrac/Ev1000 device in the first two hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard ICU monitorisation
Description: Hemodynamic resusucitation guided by the data obtained from ICU standard hemodynamic monitoring (BP, CVP) in the first 2 hours
Study: NCT04192227

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EnHAncing BehavIors through wellness TreatmentS (HABITS)
Description: Six 75-minute sessions via live video conference wherein participants will receive training in areas of health, wellness and quality of life. Classes will be supplemented with independent homework assignments and discussion on a closed social media forum with peers and facilitators.
Study: NCT04318145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL-3994 Aqueous Intravenous Solution Dose Ascention
Description: Following appropriate dilution, PL-3994 will be injected intravenously by site personnel as a bolus dose followed by continuous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL-3994 Aqueous Intravenous Solution Single Dose
Description: Following appropriate dilution, PL-3994 will be injected intravenously by site personnel as a bolus dose followed by continuous infusion
Study: NCT03551925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual Plus Occupational Therapy
Description: The IMeds consists of a three-step process that leads the client from the reflection of past performance, to goal setting, and onto strategy identification and implementation. This intervention guides the client through identifying strategies in the following six areas: altering the medication management activity, advocacy, assistive technology, environmental modifications, and securing refills on time (Schwartz et al., 2017).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: A clinical pharmacist counsels participants on proper medication adherence.
Study: NCT02045953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VENTOLIN Mini-Spacer
Description: VENTOLIN mini-spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler
Study: NCT02565251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard ICU monitorisation
Description: Hemodynamic resusucitation guided by the data obtained from ICU standard hemodynamic monitoring (BP, CVP) in the first 2 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VolumeView/Ev1000
Description: Hemodynamic resusucitation guided by the data obtained from the monitorisation with VolumeView/Ev1000 device in the next four hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VolumeView/Ev1000
Description: Hemodynamic resusucitation guided by the data obtained from the monitorisation with VolumeView/Ev1000 device in the next four hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VolumeView/Ev1000
Description: Hemodynamic resusucitation guided by the data obtained from the monitorisation with VolumeView/Ev1000 device in the next four hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VolumeView/Ev1000
Description: Hemodynamic resusucitation guided by the data obtained from the monitorisation with VolumeView/Ev1000 device in the next four hours
Study: NCT00800540

Intervention type: DRUG
Group type: OTHER
Intervention: Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension
Description: Fixed combination ophthalmic suspension

Intervention type: DRUG
Group type: OTHER
Intervention: Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension
Description: Fixed combination ophthalmic suspension

Intervention type: DRUG
Group type: OTHER
Intervention: Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution
Description: Fixed combination ophthalmic solution

Intervention type: DRUG
Group type: OTHER
Intervention: Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution
Description: Fixed combination ophthalmic solution
Study: NCT01834794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MET/CBT/CM plus NRT
Description: Behavioral Treatment for Cannabis plus Behavioral Treatment for Tobacco: both primarily delivered by computer. Additional NRT.
Study: NCT02041572

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attentional bias retraining
Description: Participants complete a computer-based intervention, which is designed to correct cognitive biases associated with PTSD by training to attend to neutral information rather than the trauma-related cue words.
Study: NCT02142543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-DeNT powder
Description: powder included dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, zinc oxide, and karaya gum

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study: NCT04021797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagal nerve stimulation
Description: The transcutaneous stimulator engages the cymba conchae in the left inner ear, compared to the left earlobe in the sham stimulation condition.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcutaneous vagal nerve stimulation
Description: The transcutaneous stimulator engages the cymba conchae in the left inner ear, compared to the left earlobe in the sham stimulation condition.
Study: NCT02145676

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA injected into predefined muscles of the study limb on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA injected into predefined muscles of the study limb on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (normal saline)
Description: Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
Study: NCT00178373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Study: NCT04232137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postpartum coffee ceremony
Description: The promise of a postpartum coffee ceremony
Study: NCT01620346

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracytoplasmic sperm injection (ICSI)
Description: ICSI is routinely used to treat couples with infertility. Sperm selection in the ICSI group was analysed under a magnification of 400x using an inverted microscope. ICSI was performed in a micro-injection dish prepared with 4 µL droplets of buffered medium (Global® w/HEPES, LifeGlobal, Connecticut, USA) and covered with paraffin oil on a heated stage at 37.0 ± 0.5°C of an inverted microscope.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic morphologically selected sperm injection
Description: IMSI is an established modified ICSI procedure that used an unstained real-time observation of spermatozoa under high-magnification. Sperm selection in the IMSI group is examined at high magnification using an inverted microscope equipped with high-power differential interference contrast optics (DIC/Nomarski). The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei and normal nuclear chromatin content are selected for injection.
Study: NCT02412657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT04278352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Relapse Prevention
Description: The intervention is a group skills training program that is delivered once weekly for eight weeks. Content focuses on mindfulness and cognitive-behavioral relapse prevention skills, including psychoeducation, experiential exercises, and between session homework assignments.
Study: NCT03851510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vector ventilator
Description: The Vector ventilator is intended to provide non-invasive ventilatory support to treat adult patients with Obstructive Sleep Apnea (OSA), or Respiratory Insufficiency with the primary cause being COPD. This device is not intended for life support. It may be used to screened for the presence and abolishment of expiratory flow limitation. It is intended to be used within the home, institution/hospital, and diagnostic laboratory environments. The vector ventilator will titrate and treat EFL using non-invasive ventilatory support.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resmon Pro
Description: The Resmon Pro uses the forced oscillation technique (FOT) which is a noninvasive method to measure the mechanical properties of the lung and airways during tidal breathing. In addition to measuring total impedance (resistance and reactance), the Resmon Pro can measure expiratory flow limitation which is a key index of respiratory obstruction
Study: NCT02532049

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63 Pfs25-IMX313

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63 Pfs25-IMX313
Study: NCT02532049

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63 Pfs25-IMX313

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63 Pfs25-IMX313

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA Pfs25-IMX313

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA Pfs25-IMX313
Study: NCT04052737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline along with standard treatment
Description: PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients. In this arm normal saline along with standard treatment will be given for active comparison.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMZ-1620 (sovateltide) along with standard treatment
Description: PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients.
Study: NCT02063555

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DAR-901

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Study: NCT03886168

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Signal processing intervention of a biomedical device
Description: This is a signal processing intervention of an FDA approved biomedical device for study participants that have received the cochlear implant based on clinical recommendations (i.e. not study related). Based on image processing of pre- and post-implant CT, cochlear segmentation, electrode scalar localization, and definition of the electrode-to-neural interface, the investigators will manipulate the stimulus delivery of the incoming signal within the FDA approved clinical software and thereby is within the electrical and clinical specifications of the FDA approved device and accompanying software.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Signal processing intervention of a biomedical device
Description: This is a signal processing intervention of an FDA approved biomedical device for study participants that have received the cochlear implant based on clinical recommendations (i.e. not study related). Based on image processing of pre- and post-implant CT, cochlear segmentation, electrode scalar localization, and definition of the electrode-to-neural interface, the investigators will manipulate the stimulus delivery of the incoming signal within the FDA approved clinical software and thereby is within the electrical and clinical specifications of the FDA approved device and accompanying software.
Study: NCT04493164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study: NCT04266574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Spectroscopy (NIRS)
Description: The anesthesiologist will apply optodes before induction of anesthesia and before preoxygenation, to detect baseline NIRS level, NIRS will be monitored continuously up to post-anaesthesia care unit (PACU) discharge, or up to three the investigator's after ICU admission.~When a decrease in NIRS value over 10% is detected, or if NIRS value is below 60%, patients will start hemodynamic optimization, to reverse the reduction in NIRS and return to baseline values, according to a predefined protocol.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Controls will be treated according to standard of care, maintaining a MAP≥65 and an adequate cardiac output according to the hemodynamic monitoring chosen by the anesthesiologist (invasive blood pressure monitoring or pulse contour monitors). NIRS will be recorded also in controls, but caring anesthesiologists will be blinded to NIRS.
Study: NCT03809624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-105 - PDL1x41BB antibody
Description: The active ingredient of INBRX-105 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-105 - PDL1x41BB antibody
Description: The active ingredient of INBRX-105 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
Study: NCT02045953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VENTOLIN Mini-Spacer
Description: VENTOLIN mini-spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VENTOLIN Mini-Spacer
Description: VENTOLIN mini-spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerochamber Plus spacer
Description: Aerochamber Plus spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerochamber Plus spacer
Description: Aerochamber Plus spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerochamber Plus spacer
Description: Aerochamber Plus spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerochamber Plus spacer
Description: Aerochamber Plus spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler